Tuesday, April 2, 2013

Compounder’s Recall Reignites Congressional Criticism of FDA




A recent recall by a New Jersey-based specialty pharmacy has reignited congressional criticism that the FDA is not doing enough to protect the public from contaminated compounded drugs.

No comments: